This inventor holds 5 USPTO granted patents and 2 published patent applications. Top assignees: Merck Frosst Canada, Inc., Merck Frosst Canada & Co., Merck + Co., Inc.. Active years: 1996-2000.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
3 out of 212 
2 out of 80 
1 out of 4,770 
Years Active: 1996-2000
Title: **Innovations by John P. Vaillancourt: A Pioneer in Biotechnology**
Introduction
John P. Vaillancourt, a distinguished inventor based in Pierrefonds, CA, has made significant contributions to the field of biotechnology through his innovative work and patents. With a total of five patents to his name, his research has focused heavily on the functional aspects of interleukin-1.beta. converting enzymes, which are crucial for various biological processes, including inflammation and cell apoptosis.
Latest Patents
Among Vaillancourt's latest innovations is a groundbreaking patent that involves the DNA encoding precursor of interleukin-1.beta. converting enzyme. This patent outlines a complementary DNA (cDNA) encoding the full-length form of ICE.sub.rel -II. This discovery is pivotal as the cDNA is not only isolated and sequenced but also cloned into expression vectors for use in recombinant hosts. The implications of this work are profound, as the cDNA and the recombinant ICE.sub.rel -II protein derived therefrom can be utilized in diagnostic kits, laboratory reagents, and various assays. Furthermore, Vaillancourt’s research opens avenues to identify compounds that affect ICE.sub.rel -II function and could potentially lead to novel treatments that modulate inflammation and apoptosis through antisense or gene therapy.
Career Highlights
John P. Vaillancourt has contributed his expertise to prominent organizations, including Merck Frosst Canada, Inc. and Merck Frosst Canada & Co. His work within these companies has solidified his reputation as a pioneer in biotechnology, allowing him to develop solutions that have impactful applications in medical research and therapeutic development.
Collaborations
Collaboration has been key to Vaillancourt’s achievements. Notable collaborations include working alongside esteemed colleagues such as Donald W. Nicholson and Ambereen Ali. These partnerships have fostered a creative environment that has been integral in advancing the research and practical applications of interleukin-1.beta. converting enzymes.
Conclusion
John P. Vaillancourt’s contributions to biotechnology exemplify the essence of innovation and the importance of collaboration in science. With his profound inventions and dedication to research, he continues to pave the way for advancements that hold great promise for the future of medical diagnostics and therapeutic interventions. His work stands as a testament to the impact that diligent inventors can have on the world.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile